PACTR202101914895981已完成未知
Initial Loss to Follow Up Among Tuberculosis Patients: The Role of Ward-Based Outreach Teams and Short Message Service (SMS) Technology
Consortium for Advanced Research Training in Africa0 个研究点目标入组 312 人开始时间: 2021年1月15日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 312
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •Patients aged 18 years old and above
- •Not yet diagnosed with TB
- •Productive cough of more than 24 hours
- •Previous TB
排除标准
- •Children less than 18 years old
- •Already on TB treatment
研究者
相似试验
招募中
2 期
Tirabrutinib maintenance versus placebo in patients with primary central nervous system lymphoma in complete remission: a randomized phase II study (JCOG2104)JPRN-jRCT2031230277agane Motoo92
已完成
不适用
Early monitoring of trastuzumab +/- pertuzumab therapy with 18F-choline PET/CT in patients with advanced disease breastcancer.NL-OMON39351Catharina-ziekenhuis23
进行中（未招募）
1 期
EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008EUCTR2013-000691-15-BEPfizer Inc, 235 East 42nd Street, New York, NY 10017500
进行中（未招募）
1 期
EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008Chronic Myeloid Leukemia (CML)MedDRA version: 20.0Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaSystem Organ Class: 100000004864EUCTR2013-000691-15-FIPfizer Inc, 235 East 42nd Street, New York, NY 10017500
进行中（未招募）
1 期
EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008Chronic Myeloid Leukemia (CML)MedDRA version: 16.0Level: LLTClassification code 10009012Term: Chronic myelogenous leukemiaSystem Organ Class: 100000004864EUCTR2013-000691-15-ESPfizer Inc, 235 East 42nd Street, New York, NY 10017820